Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19Essy Mozaffari, André C. Kalil, Aastha Chandak et al.|Clinical Infectious Diseases|2024Cited by 15
Racial and Ethnic Disparities in COVID-19 Treatments in the United StatesEssy Mozaffari, Chidinma Chima-Melton, Aastha Chandak et al.|Journal of Racial and Ethnic Health Disparities|2024Cited by 7
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment TrialGail E. Potter, Pablo Tebas, Gregory A. Deye et al.|Annals of Internal Medicine|2022Cited by 6
Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized PatientsEssy Mozaffari, Alpesh Amin, Aastha Chandak et al.|Clinical Therapeutics|2024Cited by 6
REAL-WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG UNTREATED NON-VALVULAR ATRIAL FIBRILLATION PATIENTS AND THOSE INITIATING APIXABAN, DABIGATRAN, RIVAROXABAN, OR WARFARINAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|Journal of the American College of Cardiology|2016Cited by 2